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Abstract
Background: This multicenter, open-label, prospective, single cohort study evaluated the effectiveness and safety
of adalimumab in a clinical setting reflecting the Canadian standard of care for the treatment of patients with
rheumatoid arthritis (RA).
Methods: Patients ≥ 18 years of age with a history of active RA ≥ 3 months and fulfilling Canadian requirements
for biological therapy received adalimumab 40 mg subcutaneously every other week for 12 weeks. Pre-study
DMARD treatment regimens, corticosteroids, or NSAIDs were allowed throughout the study. The primary
effectiveness outcome measure was the mean change in 28-joint disease activity score (DAS28) from baseline to
Week 12. Secondary measures included the proportion of patients achieving joint remission (DAS28 < 2.6) and
low-disease activity (DAS28 < 3.2) at Week 12, and European League Against Rheumatism (EULAR: moderate and
good) and American College of Rheumatology (ACR: ACR20, 50, and 70) responses, as well as responses in ACR
core components at Weeks 4, 8, and 12. Subgroup analysis included a comparison of patients naïve to biological
DMARD (BDMARD) therapy versus BDMARD-experienced patients. Safety was assessed in terms of adverse and
serious adverse events.
Results: A total of 879 patients (mean disease duration > 12 years) were enrolled; 772 (87.9%) completed the 12-
week period. Adalimumab treatment was associated with rapid and sustained improvements in the signs and
symptoms of RA. Significant improvements in mean DAS28 score were observed as early as Week 4. After 12
weeks of adalimumab treatment, 15.3% and 28.9% of patients achieved clinical remission and low-disease activity,
respectively. Similarly, significant improvements in ACR core components were observed as early as Week 4, with
continued improvements occurring through 12 weeks. Patients naïve to BDMARD therapy demonstrated
numerically greater clinical responses when compared with patients who had experienced prior BDMARD therapy,
although both subgroups were associated with significant improvements from baseline. The rates and types of
adverse events, as well as the results of laboratory measures, demonstrated that adalimumab was generally safe
and well-tolerated.
Conclusions: This study demonstrated that, under conditions reflective of the normal clinical practice in Canada,
adalimumab is an effective and safe treatment for patients with RA.
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* Correspondence: bharaoui@videotron.ca
1Department of Rheumatology, CHUM-Hôpital Notre Dame, Montreal,
Quebec, Canada
Full list of author information is available at the end of the article
Haraoui et al. BMC Musculoskeletal Disorders 2011, 12:261
http://www.biomedcentral.com/1471-2474/12/261
© 2011 Haraoui et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Rheumatoid arthritis (RA) is the most common inflam-
matory form of arthritis, affecting approximately 1% of
Canadian adults [1]. The long-term prognosis of RA is
poor. After 10 years, approximately 50% of patients will
have work disability. Moreover, after 20 years, up to
80% of patients will have evidence of physical disability
or joint abnormalities [2]. RA is also associated with
premature death. Indeed, the median life expectancy of
an RA population is reduced by 3 to 18 years when
compared with a non-RA population [3].
Tumor necrosis factor-alpha (TNF-a), a proinflamma-
tory cytokine, plays a critical role in mediation of the
inflammatory synovitis, cartilage matrix degradation,
and bony erosions in RA [4]. TNF-a has been shown to
be highly expressed in inflamed synovial tissue of
patients with RA, particularly at the cartilage-pannus
junction [5-7]. Adalimumab is a fully human recombi-
nant immunoglobulin G1 (IgG1) monoclonal antibody
directed against TNF-a [8,9]. Structurally and function-
ally analogous to naturally occurring human IgG1, adali-
mumab has a terminal half-life of approximately 2
weeks. Adalimumab has a high affinity for TNF-a and
does not bind to other cytokines such as lymphotoxin.
Adalimumab exerts its therapeutic effects by blocking
the interaction of TNF-a with the p55 and p75 TNF-a
cell surface receptors [8].
Adalimumab has been extensively studied for the treat-
ment of RA. The clinical efficacy and safety parameters
of recommended doses of adalimumab were determined
from the results of 4 pivotal trials (DE011, ARMADA,
STAR and DE019) [10-13]. Data from these studies have
shown that adalimumab significantly reduced the signs
and symptoms of RA. The administration of adalimumab
was also associated with significant improvements in
physical function and quality of life-related outcomes.
The beneficial effects of adalimumab were observed
whether it was administered as monotherapy or used in
combination with traditional disease-modifying antirheu-
matic drugs (DMARDs). Moreover, data from the DE019
study [11] indicated that adalimumab reduced the radi-
ologic progression of RA when administered to patients
who partially responded to methotrexate (MTX) therapy.
Interestingly, the results from the DE013 (PREMIER)
study [14] confirmed that the administration of adalimu-
mab in combination with MTX is more effective than
monotherapy with either adalimumab or MTX alone in
inhibiting the progression of structural joint damage in
patients with early RA. Results obtained from open-label-
extension studies suggest that the long-term administra-
tion of adalimumab is associated with continued efficacy
and is generally safe and well-tolerated [15-17].
While randomized, controlled trials (RCTs) are funda-
mental in assessing efficacy and tolerability of therapies,
often there are discrepancies between treatments in con-
trolled circumstances and those of usual clinical prac-
tice. In addition, practice may vary between countries
and regions. The CanACT study was designed to assess
the effectiveness and tolerability of subcutaneous (sc)
adalimumab 40 mg administered every other week
(eow) to patients with RA in a setting that reflects Cana-
dian routine clinical care.
Methods
Patients
Eligible patients were 18 years of age or older and had a
history of RA, diagnosed according to the 1987 revised
criteria of the American College of Rheumatology
(ACR) [18] for at least 3 months. To be eligible for
study entry, patients had to have active disease, which
was defined by the presence of at least 5 swollen joints
( o f6 6j o i n t se v a l u a t e d )a n d1o ft h ef o l l o w i n g :p o s i t i v e
rheumatoid factor (RF), 1 or more joint erosions present
on x-ray, or a disability index of the health assessment
questionnaire (HAQ-DI) score of at least 1. In addition,
patients had to have a history of unsatisfactory
responses or intolerance to prior antirheumatic thera-
pies, as required by local Canadian provincial guidelines
for the initiation of biological DMARDs (BDMARDs).
Concomitant prednisone dosages had to be < 10 mg/
day. All patients were screened for latent tuberculosis
and treated, when indicated, according to the Canadian
Rheumatology Association (CRA) recommendations.
Patients were excluded from the study if they had
failed more than 1 BDMARD, had received prior anti-
CD4 therapy, had a positive HIV status, or had a history
of active tuberculosis or other infections suggestive of
significant or profound immunosuppression. Patients
with a history of cancer within the past 10 years other
than successfully treated nonmetastatic cutaneous squa-
mous cell or basal cell carcinoma and/or localized carci-
noma in situ of the cervix were excluded, as were those
with a history of malignant lymphoma or leukemia,
t h o s ew i t hah i s t o r yo fn e u r o logic symptoms suggestive
of central nervous system demyelinating disease (eg,
multiple sclerosis), and those with a history of or cur-
rent acute inflammatory joint disease or an origin other
than RA (eg, systemic lupus erythematosus).
Protocol
This study was a multicenter, open-label, prospective,
single cohort study of adalimumab with concomitant
antirheumatic medications. The primary objective was
to assess the safety of adalimumab 40 mg administered
eow to patients with moderate to severe, active RA who
failed prior DMARD therapy. The secondary objectives
of the study were to assess thec l i n i c a le f f e c t i v e n e s so f
adalimumab and its impact on quality of life,
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resource utilization in these same patients.
Performed at 69 sites across Canada, this study was
conducted in accordance with ICH Good Clinical Prac-
tice and ethical principles as defined in the Declaration
of Helsinki (1989 revision) and all applicable local regu-
lations. All patients gave their written, informed con-
sent. The study protocol, informed consent form, and
patient information were reviewed and approved for
community sites by an independent Ethics Committee/
Institutional Review Board (IRB Services, Aurora,
Ontario) or by respective University Institutional review
boards.
After screening and baseline evaluations, patients
returned for assessments every 4 weeks until the Week
12 visit. Patients who completed the minimum 12-week
treatment period before adalimumab became commer-
cially available were eligible to enter a 12-week conti-
nuation phase. Results are presented for the first 12
weeks of therapy only.
All patients received adalimumab at a dose of 40 mg
sc eow. All patients were instructed in self-injection
techniques. DMARD treatment regimens as well as pre-
dnisone or equivalent (< 10 mg/day) and nonsteroidal
anti-inflammatory drugs (NSAIDs) were allowed to con-
tinue at the prestudy dose throughout the course of the
study. Other biological therapies and cyclosporine were
excluded during the study. Patients previously treated
with approved biologics (eg, etanercept, infliximab, ana-
kinra) were allowed to enter the study only if the
respective treatment was discontinued at least 2 months
prior to baseline. Cyclosporine had to be discontinued
at baseline. Intra-articular injections of corticosteroids
were allowed at any time during the course of the study
if deemed absolutely necessary to mimic real practice.
Injected joints were excluded from further evaluation.
The primary effectiveness outcome measure in this
study was the mean change in the 28-joint disease activ-
ity score (DAS28) [19] from baseline to Week 12. Sec-
ondary effectiveness assessments included the
proportion of patients achieving clinical remission
(defined as DAS28 < 2.6) and low-disease activity
(defined as DAS28 < 3.2) at Week 12, as well as the
proportion achieving European League Against Rheuma-
tism (EULAR: moderate and good) and American Col-
lege of Rheumatology (ACR: ACR20, 50, and 70)
responses at Weeks 4, 8, and 12. Other secondary out-
come measures were the mean changes in ACR core
components [tender joint count, swollen joint count,
erythrocyte sedimentation rate (ESR), physician’sg l o b a l
assessment of disease activity, patient’s global assess-
ment of disease activity, patient’s assessment of pain,
and physical function as assessed by the HAQ-DI [20]].
Patients who failed to achieve at least an ACR20
response at Week 12 were analyzed for mean changes
and mean percent changes in ACR core components
from baseline to Week 12.
Safety was assessed on the basis of adverse events
reported by patients, physical examination findings, and
laboratory evaluations. All adverse events were coded
according to the MedDRA dictionary of terms (version
9.0). All non-serious adverse events were collected from
the time of the first dose of study drug until 5 half-lives
(70 days) after discontinuation of study drug. Serious
a d v e r s ee v e n t sw e r ec o l l e c t e df r o mt h et i m et h ep a t i e n t
signed the study-specific informed consent until 5 half-
lives after discontinuation of study drug. All serious
adverse events, including those that occurred during the
70-day post-therapy period, were followed until resolu-
tion or stabilization of the event was documented.
Adverse events are reported during the first 12 weeks
plus the 70-day post-therapy period.
Statistical Analysis
All patients who received at least 1 dose of adalimumab
and returned for 1 or more follow up visits were
included in the effectiveness analysis. This included
patients who were protocol violators. Observed data
analyses were used to describe the effectiveness of adali-
mumab at Weeks 4, 8 and 12. There were no replace-
ments of missing data conducted prior to the Week 12
visit. Subgroup analysis included a comparison of
patients who were naïve to BDMARD therapy versus
patients who had experienced prior BDMARD therapy.
All patients who received at least 1 dose of adalimumab
were included in the safety analysis.
The statistical significance of the change in DAS28
from baseline to Week 12 of treatment was assessed
with the paired Student’s t-test. Linear regression analy-
sis was used to estimate and test the statistical signifi-
cance of the rate of change in the DAS28 over time.
The proportions of patients achieving ACR20, ACR50,
and ACR70 therapeutic responses at Weeks 4, 8, and 12
were calculated using the number of patients returning
for follow-up at these visits as the denominator. The
statistical significance of any change in the continuous-
scale secondary effectiveness measures, specifically phy-
sician and patient global assessment of disease activity,
patient assessment of pain, and HAQ-DI scores, was
also assessed with the paired Student’s t-test. The rate
of change in these variables over time during the 12
weeks of the study was estimated and tested for statisti-
cal significance using repeated measures linear regres-
sion analysis.
To assess the potential effect of bias due to differential
attrition, the baseline characteristics of the patients who
reached Week 12 were compared with those of patients
who did not complete the first 12 weeks of the study.
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proportion of patients with at least 1 event and the
number of events per 100 patient-years.
Results
Patient Disposition
A total of 879 patients were enrolled from 69 sites
across Canada. Of these, 772 (87.8%) completed the 12-
week study. The primary reasons for study discontinua-
tion of the remaining 107 patients were as follows: lost
to follow-up (n = 48, 5.5%), adverse events (n = 39,
4.4%), lack of efficacy (n = 15, 1.7%), withdrawal of con-
sent (n = 4, 0.5%), and protocol violation (n = 1, 0.1%).
Demographic and Baseline Characteristics
Demographic and disease characteristics at baseline
were typical of a patient population with long-standing
and moderate to severe RA (Table 1): the mean disease
duration since diagnosis was 12.5 years, while the mean
tender and swollen joint counts were 14.9 and 13.2,
respectively, the mean HAQ-DI score was 1.5, and the
mean DAS28 was 6.1.
A total of 860 (97.8%) of the patients previously
received treatment with 1 or more DMARDs at the time
of enrollment; these agents could be continued through-
out the course of the study. Of the patients enrolled,
42.2% were treated with adalimumab in combination
Table 1 Demographic and Clinical Characteristics at Baseline
Characteristics Enrolled patients
(N = 879)
Demographics Age, years 54.4 ± 11.5
Female, no (%) 692 (78.7)
White, no (%) 820 (93.3)
Disease duration, years 12.5 ± 9.7
RF > 20 IU/mL, no (%) 661 (75.2)
ACR core set Tender joint count (0-68 scale) 14.9 ± 7.1
Swollen joint count (0-66 scale) 13.2 ± 5.2
Patient’s assessment of pain, mm (0-100 mm VAS)
a 66.2 ± 22.3
Patient’s global assessment of disease activity, mm (0-100 mm VAS)
b 65.1 ± 22.7
Physician’s global assessment of disease activity, mm (0-100 mm VAS)
b 63.7 ± 17.6
HAQ-DI score (0-3 scale)
c 1.5 ± 0.6
DAS28 Score 6.1 ± 1.2
Acute phase reactants ESR (mm/hr) (normal value < 20 mm/h for men, < 30 mm/h for women) 30.3 ± 23.8
CRP (mg/L) (normal value < 10 mg/L) 24.0 ± 30.8
Quality of life HUI2 score 0.59 ± 0.22
HUI3 score 0.38 ± 0.29
DMARD therapy Receiving adalimumab + 0 DMARD, no. (%) 135 (15.4)
Receiving adalimumab + 1 DMARD, no. (%) 371 (42.2)
Receiving adalimumab + 2 DMARDs, no. (%) 284 (32.3)
Receiving adalimumab + ≥ 3 DMARDs, no. (%) 89 (10.1)
Receiving methotrexate, no (%) 549 (62.5)
Receiving leflunomide, no. (%) 248 (28.2)
Receiving sulfasalazine, no. (%) 104 (11.8)
Receiving hydroxychloroquine, no. (%) 248 (28.2)
Receiving prednisone, no. (%) 381 (43.3)
Prednisone ≤ 5 mg, no. (%) 158 (18)
Prednisone > 5 mg, no. (%) 223 (25.3)
Patients that received prior BDMARD therapy no. (%) 242 (27.5)
Patients that received etanercept no. (%) 131 (54.1)
Patients that received infliximab no. (%) 65 (26.9)
Patients that received other BDMARD no. (%) 46 (19)
*Indicating a statistical difference (P < 0.05) between those that continued after the Week 12 visit and those that did not.
a0 = no pain and 100 = severe pain.
b0 = no disease activity and 100 = extreme disease activity.
c0 = no difficulty and 3 = unable to perform activity.
ACR: American College of Rheumatology; CRP: C-reactive protein; DAS28: 28-joint disease activity score; DMARD: disease-modifying antirheumatic drug; ESR:
erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; HUI: health utility index; RF: rheumatoid factor; VAS: visual
analog scale.
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mumab in combination with 2 DMARDs, and 10.1%
were treated with adalimumab in combination with ≥ 3
DMARDs. The most frequently co-administered
DMARDs were MTX (62.5%), leflunomide (28.2%),
hydroxychloroquine (28.2%), and sulfasalazine (11.8%).
Prednisone was used concomitantly by 381 (43.3%)
patients. Of these, 223 (25.3%) received > 5 mg of pre-
dnisone/day and 158 (18.0%) received ≤ 5 mg/day. Prior
BDMARD therapy use was reported by 242 (27.5%)
patients, 131 (54.1%) of whom had received etanercept
and 65 (26.9%) of whom had received infliximab.
No differences were detected between the baseline
demographic and disease characteristics of patients who
reached the Week 12 visit and those who discontinued
before the Week 12 visit (data not shown), with the
exception of the proportion of patients that received
adalimumab without a DMARD (29.9% vs. 13.3%, P =
0.001).
Effectiveness
Mean DAS28 decreased from 6.1 (95% confidence inter-
val [CI]: 6.0, 6.2) at baseline to 4.2 (95% CI: 4.1, 4.3) at
Week 12 (P <0 . 0 0 1 ;F i g u r e1 A ) ,w i t has i g n i f i c a n t
decrease occurring as early as Week 4. From a linear
regression analysis, mean change in DAS28 (SD) was
-0.157 (0.006) per week (P < 0.001). Following 12 weeks
of treatment with adalimumab, 15.3% and 28.9% of
patients achieved clinical remission (defined as a DAS28
value < 2.6) and low-disease activity (defined as a
DAS28 value < 3.2), respectively.
Moderate and good clinical responses, as defined by
the European League Against Rheumatism (EULAR) cri-
teria [21], were observed at Week 4 for 50.1% and 11.7%
of patients, respectively (data not shown). Patients with
a good EULAR response increased steadily over time,
with 25.9% of patients achieving a good response at 12
weeks. Similar trends were observed for ACR response
criteria. Following 4 weeks of treatment, the proportions
of patients achieving ACR20, ACR50, and ACR70
improvements were 37%, 10.6%, and 2.4%, respectively
(Figure 2A). These proportions increased to 58.4%,
30.6%, and 12.7% following 12 weeks of adalimumab
therapy.
Patients experienced improvements in each of the
ACR core components during 12 weeks of adalimumab
treatment, with significant improvements occurring as
early as Week 4 (Table 2). By Week 12, the mean (SD)
number of tender joints decreased from 14.9 (7.1) to 6.8
(6.8), and the mean (SD) number of swollen joints was
reduced from 13.2 (5.2) to 6.4 (5.2). As measured on a
0-100 mm Visual Analog Scale (VAS), patient’s assess-
ment of pain decreased from a mean (SD) of 66.2 (22.3)
to 37.3 (27.5), patient’s assessment of disease activity
decreased from 65.1 (22.7) to 37.4 (27.2), and physician’s
assessment of disease activity decreased from 63.6 (17.6)
to 29.0 (22.7). The mean (SD) HAQ-DI score improved
by an average of 0.5 units from 1.5 (0.6) at baseline to
1.0 (0.7) at Week 12. In addition, significant reductions
in ESR were observed as early as Week 4, resulting in
near normal levels. At Week 12, the ESR decreased
from a mean (SD) of 30.3 (23.8) mm/h at baseline to
20.0 (18.6) mm/h (P < 0.001). Repeated measures linear
regression analysis demonstrated a significant change
over time in each of the ACR core components (P <
0.001, data not shown). A subset analysis of patients
who failed to achieve at least an ACR20 response at
Week 12 (n = 321/772, 41.6%) demonstrated reductions
in ACR core component values at Week 12 (Table 3).
Furthermore, ACR20 non-responders demonstrated >
20% improvements from baseline in tender and swollen
joint counts and in physician’s global assessment of dis-
ease activity.
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Figure 1 Changes Over Time in the Mean 28-joint Disease
Activity Score (DAS28). Mean change (95% confidence intervals
[CI]) in DAS28 in patients receiving adalimumab 40 mg
administered subcutaneously every other week with concomitant
standard antirheumatic therapy. A.) All randomized patients. The
mean DAS28 at Weeks 4, 8, and 12 were significantly lower than
the mean DAS28 at baseline (P < 0.001). B.) Subgroup analysis of
randomized patients on the basis of experience with biological
DMARD (BDMARD) therapy. The mean DAS28 at Weeks 8 and 12
was significantly lower in BDMARD-naïve patients than in patients
who experienced prior BDMARD therapy (P < 0.05).
Haraoui et al. BMC Musculoskeletal Disorders 2011, 12:261
http://www.biomedcentral.com/1471-2474/12/261
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ence with a BDMARD, a clear trend in clinical responses
was observed: patients naïve to BDMARD therapy typi-
cally demonstrated greater clinical effectiveness when
compared with patients who had experienced prior
BDMARD therapy, despite comparable baseline disease
characteristics (data not shown). For example, BDMARD-
naïve patients exhibited lower DAS28 scores at Week 12
than patients who had experienced prior BDMARD ther-
apy (4.0 versus 4.6 for BDMARD-naive and prior
BDMARD subgroups, respectively; Figure 1B). Similarly,
patients naive to BDMARD therapy demonstrated numeri-
cally higher rates of ACR20, 50, and 70 responses at Week
12 when compared with patients who had experienced
prior BDMARD therapy (Figure 2B).
Safety
A total of 551 non-serious adverse events were reported
by 371(43.4%) patients during the safety assessment per-
iod, translating into an overall rate equivalent of 2.6
events/patient-year. The majority of the adverse events
were mild to moderate in intensity. Adverse events that
o c c u r r e di nm o r et h a n1 %o ft h es t u d yp o p u l a t i o na r e
summarized in Table 4. Injection site reaction was the
most common adverse event, reported by 9.9% of the
patients. The most common injection site reaction was
injection site erythema, which was reported by 3.5% of
the patients; injection site reactions described as pruri-
tus or rash were reported by 1.4% and 2.8% of patients,
respectively. Of the treatment-emergent adverse events
considered by the investigator to be related to study
drug, injection site reaction and headache were the most
frequently reported (≥ 5% of patients). One patient
reported 2 breast cysts following 37 days of treatment
with adalimumab, which, although severe, were deemed
to be non-serious and unrelated to study drug.
A total of 19 serious adverse events were reported by
16 (1.8%) patients. The most frequently reported events
were cardiac disorders (n = 2, 0.2%) and gastrointestinal
disorders (n = 2, 0.2%). Specifically, these included 1
case of congestive heart failure (CHF), 1 case of mitral
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Figure 2 Response in American College of Rheumatology (ACR)
Criteria Following Adalimumab Treatment. Percentages of
patients who met the AC R criteria for 20%, 50%, and 70%
improvement (ACR20, ACR50, and ACR70, respectively) with
adalimumab 40 mg administered subcutaneously every other week
with concomitant standard antirheumatic therapy. A.) All randomized
patients. B) Subgroup analysis of randomized patients on the basis of
experience with biological DMARD (BDMARD) therapy.
Table 2 American College of Rheumatology Core Components and Acute Phase Reactants
ACR Core Reactant Components and Acute Phase Baseline Week 4 Week 8 Week 12
ACR Core Set Tender joint count (0-68 scale) 14.9 ± 7.1 9.4 ± 7.1* 7.8 ± 7.1* 6.8 ± 6.8*
Swollen joint count (0-66 scale) 13.2 ± 5.2 8.7 ± 5.6* 7.4 ± 5.5* 6.4 ± 5.2*
Patient’s assessment of pain, mm (0-100 mm VAS)
a 66.2 ± 22.3 45.0 ± 26.4* 40.3 ± 26.9* 37.3 ± 27.5*
Patient’s global assessment of disease activity, mm (0-100 mm
VAS)
b
65.1 ± 22.7 45.1 ± 25.7* 41.0 ± 26.7* 37.4 ± 27.2*
Physician’s global assessment of disease activity, mm (0-100 mm
VAS)
b
63.6 ± 17.6 40.7 ± 22.5* 33.5 ± 22.4* 29.0 ± 22.7*
HAQ-DI score (0-3 scale)
c 1.5 ± 0.6 1.2 ± 0.7* 1.1 ± 0.7* 1.0 ± 0.7*
Acute Phase
Reactant
ESR (mm/h) normal value < 20 mm/h 30.3 ± 23.8 20.6 ± 20.1* 20.7 ± 19.7* 20.0 ± 18.6*
*P < 0.001 vs. baseline.
a0 = no pain and 100 = severe pain.
b0 = no disease activity and 100 = extreme disease activity.
c0 = no difficulty and 3 = unable to perform activity.
ACR: American College of Rheumatology; ESR: erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; VAS: visual analog scale.
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Page 6 of 10valve incompetence, 1 case of myocardial infarction, 1
case of pulmonary edema, 1 case of pancreatitis, and 1
case of gastroesophageal reflux disease. One patient died
within the safety assessment period. The cause of death
was myocardial infarction secondary to staphylococcal
sepsis, attributed to study drug.
I na l l ,9( 1 . 0 % )p a t i e n t sr e p o r t e d1 0i n c i d e n c e so fs e r i o u s
infections within the safety assessment period. In addition
to the Staphylococcus aureus septicemia that occurred in
the patient who died, other incidences of serious infection
included 3 cases of pneumonia, 2 cases of surgical wound
infections, 1 case of postoperative infection, 1 case of foot
cellulitis, 1 case of possible septic arthritis, and 1 case of
pyelonephritis. The rate of serious infections was esti-
mated to be 2.4 events/100 patient-years.
One patient was diagnosed with basal cell carcinoma
97 days after starting study drug. This event was consid-
ered to be serious but of moderate severity and not
related to adalimumab according to the judgment of the
treating physician.
Adalimumab therapy was associated with slight
decreases in white blood cell count, neutrophils,
Table 3 American College of Rheumatology Core Components and Acute Phase Reactants for Patients Identified as
ACR20 Non-responders at Week 12
ACR Core Reactant Components and Acute Phase ACR20 Non-responder at Week 12
(N = 321/772, 41.6%)
Baseline Week 12 Change % Change
ACR Core Set Tender joint count (0-68 scale) 14.4 ± 7.8 10.6 ± 7.9 -3.8 ± 6.2 -21.6 ± 57.3%
Swollen joint count (0-66 scale) 12.9 ± 5.2 9.1 ± 5.7 -3.8 ± 5.0 -28.1 ± 41.4%
Patient’s assessment of pain, mm (0-100 mm VAS)
a 64.7 ± 24.3 55.3 ± 26.3 -9.1 ± 25.1 7.1 ± 275%
Patient’s global assessment of disease activity, mm (0-100 mm VAS)
b 64.6 ± 24.1 54.9 ± 26.6 -9.5 ± 25.1 3.3 ± 191%
Physician’s global assessment of disease activity, mm (0-100 mm VAS)
b 63.1 ± 17.8 42.7 ± 24.1 -20.5 ± 23.0 -31.1 ± 38.2%
HAQ-DI score (0-3 scale)
c 1.6 ± 0.6 1.4 ± 0.7 -0.2 ± 0.4 -14.7 ± 37.1%
Acute Phase Reactant ESR (mm/h) normal value < 20 mm/h 29.6 ± 23.7 23.5 ± 21.6 -5.9 ± 15.8 -9.2 ± 76.8%
All values are mean ± standard deviation.
a0 = no pain and 100 = severe pain.
b0 = no disease activity and 100 = extreme disease activity.
c0 = no difficulty and 3 = unable to perform activity.
ACR: American College of Rheumatology; ESR: erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; VAS: visual analog scale.
Table 4 Proportion and Rates of Adverse Events that are Probably or Possibly Related to Adalimumab Observed in
More Than 1% of the Patients
Adverse events observed in
> 1% of the patients
(probably or possibly related to adalimumab)
No. of Events No. of Patients Patients (%) Events per 100 patient-years
Injection site reaction NOS
a 145 87 9.9 39.0
Headache 63 46 5.2 16.9
Injection site erythema 55 31 3.5 14.8
Nausea 38 26 3 10.2
Rash NOS 26 25 2.8 7.0
Diarrhea NOS 27 22 2.5 7.3
Fatigue 21 16 1.8 5.6
Upper respiratory tract infection NOS 17 16 1.8 4.6
Injection site pruritus 23 13 1.5 6.2
Dizziness 12 12 1.4 3.2
Pruritus 14 12 1.4 3.8
Rheumatoid arthritis 14 12 1.4 3.8
Nasopharyngitis 13 11 1.3 3.5
Adverse drug reaction 11 10 1.1 3.0
Injection site rash 11 10 1.1 3.0
Urinary tract infection NOS 10 9 1 2.7
aDefined as localized injection-site bruising, burning, dermatitis, erythema, induration, inflammation, irritation, mass, edema, pain, pruritus, rash, stinging, swelling,
and warmth.
NOS: not otherwise specified.
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Page 7 of 10monocytes, and platelet counts and with modest
increases in lymphocytes and eosinophils (data not
shown). However, none of these changes were consid-
ered to be clinically relevant. Mean changes in clinical
chemistry parameters also were small and not clinically
relevant. No patient had a clinically relevant shift in any
urinalysis value. Furthermore, changes in mean vital
signs (systolic and diastolic blood pressure, heart rate,
respiratory rate, and body temperature) were small and
clinically unremarkable (data not shown).
Discussion
The relationship between observational studies and
RCTs is widely considered to be complementary, not
alternative [22]. Open-label observational studies offer
greater understanding of the effectiveness of medications
in real-world clinical practice, which cannot be provided
by RCTs. In addition, the inclusion of patients and
treatments reflecting varying clinical practices, rather
than the narrow range included in RCTs, offers a better
environment to study the safety profile of drugs and to
determine their tolerability profile.
CanACT is the largest observational study designed to
evaluate the effectiveness and safety of adalimumab in a
setting reflective of the Canadian clinical practice for
the treatment of RA. In this study, patients who failed
prior DMARD therapy received sc adalimumab eow;
patients were allowed to continue antirheumatic treat-
ment (eg, DMARDs, low-dose corticosteroids, NSAIDs,
analgesics, etc.), with the exception of BDMARDs and
cyclosporine. Patients had experienced many years of
active disease prior to enrollment [mean (SD) = 12.5
(9.7) years], a result that is reflective of access to care in
Canada and consistent with data from many European
and American BDMARD registries [23]. The results of
this 12-week study support the effectiveness and toler-
ability of adalimumab under conditions of routine clini-
cal care.
As demonstrated through the examined effectiveness
measures, responses to adalimumab therapy were rapid.
Significant reductions from baseline were observed as
early as 4 weeks from the start of therapy. At this time
point, more than a third (37.6%) of the patients already
were classified as ACR20 responders. Significant changes
in DAS28 also were observed at this visit. Interestingly,
improvements in DAS28 were numerically greater dur-
ing the four weeks that followed the initiation of adali-
mumab than between any of the subsequent visits. At
Week 12, more than 15% of patients achieved clinical
remission as defined by DAS28 < 2.6, and nearly double
(28.9%) achieved a low-disease state (DAS28 < 3.2).
Further, clinically important ameliorations in physical
functions were observed in the first few weeks that fol-
lowed the initiation of adalimumab therapy. These
changes from baseline were maintained over time. Even
patients who failed to satisfy ACR20 response criteria
experienced significant improvements in most of the
ACR core component measures with the exception of
patient’s global and pain evaluations.
The effectiveness of adalimumab against active RA
that is unresponsive or only partially responsive to stan-
dard antirheumatic therapy demonstrated in this real-
world trial confirms the results of other placebo-con-
trolled studies in which adalimumab was administered
either as monotherapy [13], in combination with MTX
[11,12,14,15], or concomitantly with standard antirheu-
matic therapy [10]. Further, these results support earlier
findings that adalimumab is efficacious even for patients
who have failed or become intolerant to other TNF-a-
antagonist therapies [24]. The data presented in the pre-
sent analysis suggest that patients who are naïve to
BDMARD therapy tend to achieve better disease status
over a short period of time than patients with prior
exposure to BDMARDs. While these results strongly
support the use of adalimumab as a first line biological
agent, adalimumab remains a viable option as a second
line biological agent.
Adalimumab was well-tolerated in the CanACT study
population with 87.8% completing the 12-week study.
Only 39 of the 879 (4.4%) enrolled patients discontinued
because of an adverse event. Most of the adverse events
reported in this study were nonserious and considered
to be either mild or moderate in intensity. Injection site
reaction, which is frequently associated with subcuta-
neously administered agents, was the most commonly
reported adverse event.
Nine patients in the study reported serious infections,
resulting in an estimated rate of 2.4 events/100 patient-
years. Similar rates have been observed during studies in
which patients were treated with adalimumab plus MTX
[11,14,15], or with standard antirheumatic therapy [10].
Patients treated with TNF-a antagonists are considered
to be at increased risk of developing serious infections.
However, the rate of serious infections reported in the
present study was less than both the rate in the adali-
mumab clinical trial safety database (4.7/100 patient-
years) and the rate in the general RA population as
reported in the literature (3.1-9.6/100 patient-years)
[25], a finding that may reflect the short duration of the
study. There were no reported cases of tuberculosis dur-
ing the study.
Congestive heart failure (CHF) was reported as a
study-drug-related serious adverse event in 1 patient in
the present study. This is in keeping with results from
other clinical trials involving adalimumab [25,26], in
which CHF has been described in patients both with
and without a history of the disease. Proportionally,
more patients with a history than without a history of
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Page 8 of 10CHF have reported this as an adverse event (7% vs.
0.3%). However, it should be noted that patients with a
history of CHF were usually excluded from clinical
trials. No cases of lupus or lupus-like syndrome
occurred in patients in the present study, which is in
accord with observations from previous clinical trials
that demonstrated that these conditions are rarely asso-
ciated with adalimumab [25,26].
The aforementioned results demonstrate that the
safety profile of adalimumab is similar to that previously
reported in controlled trials. In studies in which adali-
mumab was administered concomitantly with MTX
[10-12,14,15], this combination was found to be safe
and well-tolerated.
Conclusions
In conclusion, the results of the present study demon-
strate that adalimumab 40 mg given sc eow was effective
in producing clinically important and statistically signifi-
cant reductions in the signs and symptoms of disease.
In addition, adalimumab therapy was associated with
significant improvements in the physical functioning of
patients with RA. The safety profile of adalimumab
observed in this patient group was comparable with that
of previous studies with this agent. Taken together, the
current study supports the use of adalimumab 40 mg sc
eow in the management of patients with RA who have
not responded satisfactorily or who have proved intoler-
ant to antirheumatic DMARD therapies.
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